Device Trial Radar · NCT06556563
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
741
Planned (sponsor's estimate)
Start
Feb 3, 2025
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- NovoCure GmbHNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Aug 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Conditions
- Glioblastoma
Interventions
Optune® deviceDevice
Optune® device delivering TTFields therapy at 200 kHz.
TemozolomideDrug
Temozolomide per approved labeling.
PembrolizumabDrug
Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
PlaceboDrug
Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: 24 months
Locations
102 sites in 12 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
University of Southern California
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
99 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.